Abstract: The present disclosure relates to compositions comprising mixtures of hydroxypropyl-?-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-?-cyclodextrins.

Abstract: The present disclosure relates to compositions comprising mixtures of hydroxypropyl-?-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-?-cyclodextrins.

Abstract: An absorbent article comprising an absorbent gelling material (AGM) having an encapsulated compound of one or more odor controlling organic compounds disposed upon a surface thereof is described. Alternatively, an AGM particle comprising an encapsulated reactive compound of one or more odor controlling organic compounds disposed as a surface coating thereon is described. Additionally, a method to manufacture an absorbent article is described. The method provides for the steps of: a) providing a solution in a solvent system, the solution has an encapsulating agent and one or more odor controlling organic compounds as a surface coating; b) applying an amount of the solution to a surface of an AGM particle; and, c) incorporating the AGM particle having the solution applied thereto into the absorbent article.

Abstract: The present application provides processes for the purification of ferric carboxymaltose, the process includes the steps of dissolving crude ferric carboxymaltose in a first solvent; charging the ferric carboxymaltose solution in a reaction vessel with a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.

Abstract: Provided is a novel multifunctional cyclodextrin polymer capable of adsorbing the organic pollutants dissolved in water super-fast. A cyclodextrin polymer with a three-dimensional network structure and quaternary ammonium salt functional groups is obtained by mixing and crosslinking a cyclodextrin, a rigid crosslinking agent, a non-rigid crosslinking agent and a quaternary ammonium salt at certain temperature. The polymer is capable of adsorbing the organic pollutants dissolved in water at an ultra-fast rate, and the polymer after adsorption is easily regenerated and can be repeatedly used multiple times without causing a decrease in the adsorption property.

Abstract: Disclosed are adsorption complexes that include 1-methylcyclopropene (1-MCP) and a metal coordination polymer network (MCPN), wherein the MCPN is a porous material, and the 1-MCP is adsorbed into the MCPN. Also disclosed are kits for containing 1-MCP that include the adsorption complex in a 1-MCP-impermeable package. Also disclosed are methods of releasing 1-methylcyclopropene (1-MCP) from the kit that include the application of aqueous fluids, heat, and/or pressure.

Abstract: A novel cyclodextrin polymer with ultra-fast adsorption performance is provided. A cyclodextrin polymer having a three-dimensional network structure is obtained by mixing and crosslinking a cyclodextrin with a rigid crosslinking agent and a non-rigid crosslinking agent at a certain temperature. The polymer is capable of adsorbing a plurality of organic pollutants in water at an ultra-fast rate, and the polymer after adsorption is easily regenerated by simple washing at a normal temperature, and is repeatedly used without causing a decrease in adsorption performance.

Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.

Abstract: The present invention relates to a process for preparation of 6-perdeoxy-6-per-chloro gamma-cyclodextrin which is a key intermediate useful in the synthesis of Sugammadex sodium. The present invention further relates to a process for preparation and purification of Sugammadex sodium.

Abstract: A process for preparing sugammadex sodium comprising: reacting a ?-cyclodextrin of formula I with a halogenating agent in the presence of N-methyl-2-pyrrolidone to provide a compound of formula II; and reacting the compound of formula II with 3-mercapto propionic acid in the presence of a sodium base and an organic solvent to provide sugammadex sodium formula III: wherein X in formula II is halo.

Abstract: Disclosed are cyclodextrin-based metal organic frameworks comprising a metal cation and cyclodextrin or a cyclodextrin derivative. These metal organic frameworks are permanently porous and capable of molecule storage.

Abstract: A method for fractionating dextrin, belonging to the technical field of food processing. In principle, the method for fractionating dextrin of the present invention is based on the fact that the dextrin is incompatible with polyethylene glycol in aqueous solution and a larger molecular weight of the dextrin results in more significant incompatibility with polyethylene glycol. Accordingly, the stepwise precipitation of dextrin components having a molecular weight from large to small may be realized by gradually increasing the concentration of polyethylene glycol by gradually adding polyethylene glycol to dextrin in aqueous solution.

Abstract: A controlled-release oral pharmaceutical composition of at least an active agent, including: a) a lipophilic matrix consisting of lipophilic compounds and/or amphiphilic compounds; and b) an hydrophilic matrix, wherein the hydrophilic matrix includes at least an indigestible polysaccharide, the active ingredient being dispersed in the lipophilic and/or the hydrophilic matrix. The present invention also relates to a process for the preparation of such a pharmaceutical composition.

Abstract: The present invention relates to a fibrous starch with enhanced emulsifying capacity and emulsifying stability, and low-fat mayonnaise and margarine compositions using the same. More specifically, disclosed are fibrous starch which has an increased starch particle size and exhibits improved emulsifying capacity and emulsion stability, prepared by heat-treating starch at a temperature lower than a gelatinization temperature, phosphorylating the starch and further heat-treating the starch sample at a high temperature, and low-fat mayonnaise and margarine compositions in which the content of cooking oil is reduced by 50% or more by adding the fibrous starch with enhanced emulsifying capacity thereto.

Abstract: Disclosed are cyclodextrin-based metal organic frameworks comprising a metal cation and cyclodextrin or a cyclodextrin derivative. These metal organic frameworks are permanently porous and capable of molecule storage.

Abstract: The present invention relates to channel type cyclodextrin crystals, particularly channel type ?-cyclodextrin crystals, to a method for producing channel type cyclodextrin crystals, and products comprising channel type cyclodextrin crystals.

Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.

Abstract: The invention relates to a complex of pure anthocyanidin and a sulfoalkyl ether ?-cyclodextrin, which complex can be formulated as an aqueous solution and as a solid, and a method for producing such a complex. Complexes according to the invention are storage-stable and can be well formulated as an aqueous solution.

Abstract: The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s) in the presence of the hydrophilic polysaccharide derivative wherein the hydrophilic polysaccharide derivative may have a crosslinkable group(s).

Abstract: The invention provides a method of producing a polyrotaxane having cyclic molecules, a linear molecule threaded through the cyclic molecules to form a clathrate, and blocking groups at both ends of the linear molecule to prevent the separation of the cyclic molecules from the linear molecule, the method including forming the blocking groups by reacting the linear molecule piercing the cyclic molecules, the linear molecule having carboxyl groups at both ends thereof, with a blocking agent having an amino group in the absence of a solvent or in at least one organic solvent selected from the group consisting of aprotic amide solvents and aromatic hydrocarbons, and further in the presence of 2.0 mol to 100 mol of a triazine-based amidating agent per 1 mol of the carboxyl groups in the linear molecule.

Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

Abstract: Methods for performing analytical reactions and compositions for use in such methods, where the methods have reduced signal levels deriving from non-specific adsorption of detected reagents to other components of the analytical method, e.g., other reagents, solid phase components, vessels, etc.

Abstract: In certain embodiments the methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease, and/or of promoting the processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway are provided. In certain embodiments the methods involve administering, or causing to be administered, to a subject in need thereof certain formulations comprising or more active agent(s) selected from the group consisting of tropisetron disulfiram, honokiol, nimetazepam, and/or derivatives or analogs thereof.

Abstract: Hyper-branched maltodextrins having a dextrose equivalent (DE) between at least 8 and at most 15 and a molecular weight or Mw between at least 1,700 and at most 3,000 daltons, characterized in that same have: a 1,6 glucoside bond content between at least 30 and at most 45%; a soluble indigestible fiber content, which is determined according to the AOAC No. 2001-03 method, between at least 75 and at most 100%; and a hypoglycemic capacity expressed according to a test A, which:—in vitro, results in an 80 to 90% reduction of the ?-amylase hydrolysis of standard maltodextrins, and—in situ, by a 30 to 45% reduction in the intestinal digestive activity of standard maltodextrins.

Abstract: A medium which comprises a fibroblast growth factor (FGF), and a sulfated compound or a pharmaceutically acceptable salt thereof at a concentration which promotes the growth of a stem cell in the presence of FGF, is useful for culturing stem cells.

Abstract: The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material. Furthermore, the present invention relates to the use of the sorbent according to the invention for the purification of organic molecules, in particular pharmaceutically active compounds, preferably in chromatographic application.

Abstract: Absorbent articles comprising one or more complexed or encapsulated compounds compounds selected from: melonal, adoxal, trans-2-hexenal, ligustral, Floral Super, Florhydral, 5-methyl-2-thiophene-carboxaldehyde, hydratropic aldehyde, undecenal, 9-undecenal, 10-undecenal, trans-4-decenal, cis-6-nonenal, isocyclocitral, precyclemone b, (E)-2,(z)-6-nonadienal, undecyl aldehyde, methyl-octyl-acetaldehyde, Lauric aldehyde, silvial, vanillin, floralozone; are particularly effective in reducing malodors coming from degradation of proteinaceous materials such as food, menses or feces.

Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.

Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.

Abstract: The present invention relates to a composition including a mix of a polysaccharides having: 15% to 50% of glucoside linkages 1-6; a reducing sugar content of less than 20%; a polymolecularity index of less than 5; an average molecular weight with number Mn of less than 4500 g/mole and at least one active agent for treating stress, anxiety and depressive behavior, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals. The present invention also relates to the use of the polysaccharide for treating stress, anxiety or depressive behavior, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals.

Abstract: The present invention provides a method for the production of ?-CD, comprising making a starch slurry, incubating with ?-CGTase and isoamylase simultaneously for ?-CD production, forming a complex of ?-CD and an organic complexant, and purifying ?-CD from the complexant. The present invention provides a simple and cost-effective method for producing high purity ?-CD, which has a short production cycle, a high conversion rate, and is adaptable to large-scale industrial production.

Abstract: The present invention relates to a novel method for synthesizing a composition of polymers, copolymers, terpolymers and tetrapolymers, and to the use thereof, said composition being made from: cyclodextrins, in particular ?-cyclodextrin, ?-cyclodextrin, ?-cyclodextrin, the derivatives or corresponding mixtures thereof, and/or calix[n]arene(s) and/or of calix[n]arene derivative(s) and/or a mixture of two or more different calix[n]arenes selected from calix[n]arenes (n=4-20) and/or the derivatives thereof, and to the uses thereof. A method was developed on the basis of direct-melt polycondensation. The invention can be used in the pharmaceutical, human medicine, veterinary medicine, chemistry, separation chemistry, environmental, electronics, biological, diagnostics, phytosanitation, medicinal food, agri-food, and cosmetics fields, and in the nutraceutical field and in the field of molecular imprints (MIP).

Abstract: Compounds which inhibit Wza-mcdiated polysaccharide transport are useful in the prevention or treatment of bacterial infection, in particular of E. coli infection. The compounds are typically cyclic oligosaccharides such as cyclodextrins, which bear positively charged functional groups at the primary carbon position.

Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

Abstract: Provided is a silica particle coated with ?-cyclodextrin, wherein said cyclodextrin is attached to said silica particle via at least one crosslinking agent and/or at least one copolymer. Also provided are methods of removing contaminants from a flowing or stationary liquid phase comprising the step of contacting said liquid phase with the silica particle coated with ?-cyclodextrin.

Abstract: The present invention provides cyclodextrin-curcumin inclusion complexes, self-assemblies thereof; methods for making such inclusion complexes and self-assemblies, and methods for their use.

Abstract: A deodorant composition contains ?-cyclodextrin, a fixative, a preservative, and a solvent.

Abstract: A novel process for the preparation of 6-perdeoxy-6-per-halo Gamma cyclodextrin which is a useful intermediate in the synthesis of Suggamadex is disclosed in the invention. The process involves by reacting Gamma cyclodextrin with phosphorous halide in presence of organic solvent.

Abstract: Provided is a novel IgA secretion promoter useful as a mucosal immunity stimulation agent and a method of promoting IgA secretion in a body of animal to stimulate mucosal immunity. A significant action of promoting IgA secretion was observed in oral administration of indigestible dextrin.

Abstract: Fabrication and arrangement of nanoparticles into one-dimensional linear chains is achieved by successive chemical reactions, each reaction adding one or more nanoparticles by building onto exposed, unprotected linker functionalities. Optionally, protecting groups may be used to control and organize growth. Nanoparticle spheres are functionalized in a controlled manner in order to enable covalent linkages. Functionalization of nanoparticles is accomplished by either ligand exchange or chemical modification of the terminal functional groups of the capping ligand. Nanoparticle chains are obtained by a variety of connectivity modes such as direct coupling, use of linker molecules, and use of linear polymeric templates. In particular, a versatile building block system is obtained through controlled monofunctionalization of nanoparticles.

Abstract: Hydrophilic coating compositions and methods to make and use the compositions are disclosed. The coatings include one or more amphiphilic cyclodextrins, with one or more hydrophilic groups in place of primary hydroxyl groups, and one or more hydrophobic groups in place of secondary hydroxyl groups. The hydrophobic surface of the cyclodextrin faces the binder particles, while the hydrophilic surface is exposed to the exterior, thus providing a hydrophilic and self-cleaning property to the coating.

Abstract: This application discloses cyclodextrin-modified materials for carrying drugs and other active agents, such as nucleic acids. Compositions are also disclosed of cyclodextrin-modified materials that release such active agents under controlled conditions. The invention also discloses compositions of cyclodextrin-modified polymer carriers that are coupled to biorecognition molecules for assisting the delivery of drugs to their site of action.

Abstract: The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.

Abstract: A direct compression formulation suitable for preparing buccal and/or sublingual and dosage forms incorporates a combination of a non-ionic polymeric solubility enhancer, a mucoadhesive polymer, a filler, a disintegrant, and a pharmaceutically active agent. Cannabinoid-cyclodextrin complexes exhibiting an improved property selected from improved stability, higher product yield and improved product uniformity may be obtained by complexing the cannabinoid with the cyclodextrin in a liquid medium containing an antioxidant. To enhance stability, product yield and/or product uniformity, complexing may be done while the liquid medium is in contact with an atmosphere having a very low oxygen content.

Abstract: A (meth)allylsilane compound chemically bonded to various alcohol derivatives including polyol derivatives such as saccharides, is raw material used to cause a substrate to express functionalities such as a defogging property and separation characteristics for column chromatography, can be easily prepared, is easily purified, and is stable and easy to handle, and a functional material in which those functionalities are expressed, while silyl group-containing groups are conveniently carried at a high density on the surface of the substrate, by using the (meth)allylsilane compound as a silane coupling agent for silane-coupling to the substrate. The (meth)allylsilane compound includes a (meth)allylsilyl group-containing alkyl group or a (meth)allylsilylalkyl group-containing aralkyl group that is bonded to an alcohol derivative.

Abstract: A stable complex of tomoxiprole with 2-hydroxypropyl-beta-cyclodextrin with fast dissolution rate and rapid absorption wherein amorphous tomoxiprole forms a complex with 2-hydroxypropyl-beta-cyclodextrin in about equimolecular ratio. The complex shows a remarkably faster dissolution rate and absorption with respect to crystalline tomoxiprole and is particularly suitable for the production of pharmaceutical oral dosage forms, such as tablets and capsules, where rapid onset of therapeutical action is required. A method of manufacture of the complex is also described and claimed.

Abstract: This disclosure relates to cyclodextrin-based drug delivery agents that comprise a cyclodextrin moiety covalently linked to a moiety of a gemini surfactant. Pharmaceutical compositions comprising the drug delivery agent and a therapeutic agent are also disclosed.

Abstract: Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. The concentration of chlorine dioxide in said solid form is greater than approximately 5.8 percent by weight. Certain exemplary embodiments can provide a method comprising forming a solid complex comprising chlorine dioxide and cyclodextrin, wherein a concentration of chlorine dioxide in the solid complex is greater than 5.8 percent by weight.